Clinical Trial Update: Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating olaparib with liposomal doxorubicin in resistant advanced ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Olaparib (Olaparib)
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: Grupo Español de Investigación en Cáncer de Ovario | Conditions: Advanced Ovarian Cancer | Phase 2 | Status: COMPLETED